Yissum - Research Development Company of the Hebrew University

New Alumina-Entrapped Adjuvant Formulation for Vaccines

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Immunology
Project ID : 7-2011-2623

Yissum - Research Development Company of the Hebrew University

Description of the technology

Categories

Antibodies, Vaccinations, Drug delivery, Immunology, Adjuvants, Alumina

Development Stage

In vivo proof of concept

The lack of suitable adjuvants is considered the main obstacle in the development of new vaccines against incurable diseases.

Our Technology

  • An entrapment methodology of proteins in alumina
  • Alumina polymerization by the sol-gel process
  • Antigen-specific IgG titers exceeding 1:1,000,000 obtained in several mice using a single immunization (prime only) with low amount of antigen (7.2ugr x 1 vs. 25ugr x 3 in conventional adsorbed vaccines).
  • Antigen-specific IgG titers exceeding 1:256,000 obtained using extremely low antigen concentrations (2.5ugr, equivalent to 2 conventional immunizations using only 5% of the amount of antigen.

Fig. 1: Comparison of antigen-specific IgG titer following a single immunization with variuos composite alumina entrapped vaccines (A-4, C-3, D-1, D-2, D-3, D-4, D-5) to

immunization with antigen only (B-1) and to immunization with conventional alumina adsorbed vaccines (B-3, Alhydrogel, Sigma). All vaccines contained 7.2ug antigen

(Ovalbumin grade V, Sigma) and 25ug Al3+ in the form of alumina, except B-1 which contained antigen only

Advantages

  • The based on Alumina adjuvants, FDA approved for human use
  • Enhanced immune response - both humoral and cellular (TH1 & TH2)
  • Vaccine stability: thermal, pH, radiation
  • Controlled release of the antigen
  • Controlled release of an organic adjuvant
  • Increasing the repertoire of existing vaccine adjutants; synergism
  • Reduced toxicity
  • Convenient administration: Oral, nasal, pulmonary and topical
  • Entrapment of live or attenuated cells and cell lysate
  • Combined alumina entrapped and adsorbed matrices

Expected Impact

  • Reducing the number of required immunizations to obtain a safe, potent immune response and a long-lasting immunological memory.
  • The technology enables to prolong its shelf-life and to allow less restrictive storage condition. Therefore, enabling price reduction

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

David Avnir
HUJI, Faculty of Science
The Institute of Chemistry

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.